https://www.thebodypro.com/category/hiv-policy-advocacy/tag/hepatitis-c

The Latest

Promo Image

This Week in HIV Research: Do We Need New Statin Guidelines?

Cholesterol guidelines may underestimate statin value; shifting from Ryan White CARE Act to Affordable Care Act coverage; HCV seroconversion and CD4 count suppression; HCV reinfection odds by risk group.

National Viral Hepatitis Action Plan and National HIV/AIDS Strategy

First Listening Session Held at USCA to Inform Updates to National HIV/AIDS Strategy and National Viral Hepatitis Action Plans

The U.S. Department of Health and Human Services was at USCA 2018 to hear from community members about their ideas on priorities and issues to be addressed in updates to the National HIV/AIDS Strategy and National Viral Hepatitis Action Plan, both of...

HHS's Corinna Dan Discusses Impacts of Viral Hepatitis and Equity Issues Img

HHS's Corinna Dan Discusses Impacts of Viral Hepatitis and Equity Issues

On the third day of the 2018 U.S. Conference on AIDS (USCA) Corinna Dan, R.N., M.P.H., viral hepatitis policy advisor at HHS's Office of HIV/AIDS and Infectious Disease Policy, shared information from her conference presentation.

Mavyret Approved as Eight-Week HCV Treatment Regimen, Including for Those With Mild Cirrhosis Img

Mavyret Approved as Eight-Week HCV Treatment Regimen, Including for Those With Mild Cirrhosis

A combination of glecaprevir and pibrentasvir (Mavyret), has been approved for hepatitis C treatment, for any genotype, with a treatment duration of only eight weeks -- four weeks less than most other current regimens.

FDA Approves Vosevi for Hepatitis C Img

FDA Approves Vosevi for Hepatitis C

"Vosevi provides a treatment option for some patients who were not successfully treated with other HCV drugs in the past."

FDA Approves Epclusa for Treatment of Chronic Hepatitis C Virus Infection Img

FDA Approves Epclusa for Treatment of Chronic Hepatitis C Virus Infection

The U.S. Food and Drug Administration has approved Epclusa (sofosbuvir/velpatasvir) to treat adult patients with chronic hepatitis C virus. It is the first to treat all six major forms of HCV.

Money Trail: Some Guidance for the Journey Img

In the Golden Age of the Hep C Cure, Discount Deals Tie Doctors' Hands

Who has the power to prescribe medications? In the ongoing struggle to cure the estimated 3.2 million people living with chronic hepatitis C virus (HCV) infection in the U.S., the answer may not be who you think.

Test for HIV, Hepatitis C and Hepatitis B Approved by FDA Img

Test for HIV, Hepatitis C and Hepatitis B Approved by FDA

On Jan. 9, the U.S. Food and Drug Administration (FDA) approved a three-in-one test that detects HIV, hepatitis C and hepatitis B.

New HCV Option Effective, Safe, Well-Tolerated -- and Use Will Likely Be Driven by Payors Img

New HCV Option Effective, Safe, Well-Tolerated -- and Use Will Likely Be Driven by Payors

The U.S. Food and Drug Administration approved yet another hepatitis C treatment option on Dec. 19. The new combination, called Viekira Pak, may create the first major competition for Harvoni, which was approved earlier this year.